Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
2025-04-02 03:30
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
2025-03-21 08:38
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
2025-03-18 06:52
Telix Adds Lead-212 Isotope Production Capability
2025-03-13 06:48
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
2025-03-04 05:58
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
2025-02-26 08:49
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
2025-02-20 20:23
Illuccix® Approved in the United Kingdom
2025-02-13 05:30
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
2025-01-31 06:01
Telix Completes Acquisition of RLS (USA) Inc.
2025-01-28 05:40
Illuccix® Receives European Approval
2025-01-17 06:14
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
2025-01-14 05:43
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
2025-01-13 15:12
Scintimun® Commercialization Partnership with Curium Pharma
2025-01-13 13:08
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
2025-01-13 06:34
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
2024-12-31 04:45
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
2024-12-30 06:00
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
2024-12-19 17:02
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
2024-11-28 17:22
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
2024-11-19 06:24
1
2
3
4
5
9